Published in Blood Weekly, October 30th, 2008
Presented by Professor Robbert de Winter, M.D., Ph.D., of the Academic Medical Center in Amsterdam at the Transcatheter Cardiovascular Therapeutics symposium, TCT 2008, in Washington, D.C., the data from 3,200 patients were a target lesion revascularization (TLR) rate of 5%, a subacute thrombosis (SAT) rate of 0.4%, a late stent thrombosis (LST) rate of 0.3%, and a major adverse cardiac events (MACE) rate of 8.5%.
"The data further support the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.